Iradimed Valuation
| IRMD Stock | USD 61.80 0.26 0.42% |
At this time, the firm appears to be undervalued. Iradimed retains a regular Real Value of $70.1 per share. The prevalent price of the firm is $61.8. Our model calculates the value of Iradimed from evaluating the firm fundamentals such as Return On Equity of 0.24, current valuation of 735.52 M, and Return On Asset of 0.15 as well as inspecting its technical indicators and probability of bankruptcy.
Price Book 8.7258 | Enterprise Value 735.5 M | Enterprise Value Ebitda 31.3876 | Price Sales 10.4557 | Forward PE 35.0877 |
Undervalued
Today
Please note that Iradimed's price fluctuation is very steady at this time. Calculation of the real value of Iradimed is based on 3 months time horizon. Increasing Iradimed's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Iradimed stock is determined by what a typical buyer is willing to pay for full or partial control of Iradimed Co. Since Iradimed is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Iradimed Stock. However, Iradimed's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 61.8 | Real 70.1 | Target 71.0 | Hype 62.49 | Naive 62.83 |
The real value of Iradimed Stock, also known as its intrinsic value, is the underlying worth of Iradimed Company, which is reflected in its stock price. It is based on Iradimed's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Iradimed's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Iradimed Co helps investors to forecast how Iradimed stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Iradimed more accurately as focusing exclusively on Iradimed's fundamentals will not take into account other important factors: Iradimed Cash |
|
Iradimed Total Value Analysis
Iradimed Co is currently expected to have valuation of 735.52 M with market capitalization of 785.79 M, debt of 154.69 K, and cash on hands of 55.59 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Iradimed fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
735.52 M | 785.79 M | 154.69 K | 55.59 M |
Iradimed Investor Information
About 37.0% of the company shares are held by company insiders. The company last dividend was issued on the 20th of May 2025. Based on the measurements of operating efficiency obtained from Iradimed's historical financial statements, Iradimed Co is performing exceptionally good at this time. It has a great probability to report excellent financial results in August.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Total Cash From Operating Activities | 26.9 M | 25.6 M |
|
|
Iradimed Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Iradimed has an asset utilization ratio of 74.49 percent. This indicates that the Company is making $0.74 for each dollar of assets. An increasing asset utilization means that Iradimed Co is more efficient with each dollar of assets it utilizes for everyday operations.Iradimed Ownership Allocation
The market capitalization of Iradimed is $785.79 Million. Over half of Iradimed's outstanding shares are owned by outside corporations. These outside corporations are typically referred to as corporate investors that purchase positions in a given instrument to benefit from reduced trade commissions. Please take into account that even companies with profitable outlook can generate negative future returns on their equity. If the true value of the firm is less than the current market value, you may not be able generate positive returns on investment in the long run.Iradimed Profitability Analysis
The company reported the previous year's revenue of 73.24 M. Net Income was 19.23 M with profit before overhead, payroll, taxes, and interest of 57.8 M.Iradimed Past Distributions to stockholders
| 30th of May 2025 | ||
| 5th of March 2025 | ||
| 25th of November 2024 | ||
| 30th of August 2024 | ||
| 30th of May 2024 | ||
| 12th of January 2024 |
Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Iradimed's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Iradimed and how it compares across the competition.
About Iradimed Valuation
The stock valuation mechanism determines Iradimed's current worth on a weekly basis. Our valuation model uses a comparative analysis of Iradimed. We calculate exposure to Iradimed's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Iradimed's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 56.3 M | 29.8 M |
Iradimed Quarterly Retained Earnings |
|
A single share of Iradimed represents a small ownership stake in the entity. As a stockholder of Iradimed, your percentage of company ownership is determined by dividing the number of shares you own by the total number of shares outstanding and then multiplying that amount by 100. Owning stock in a company generally confers both corporate voting rights and income from any dividends paid to the stock owner.
Iradimed Dividends Analysis For Valuation
As of July 5, 2025, Dividends Paid is expected to decline to about 8.5 M. As of July 5, 2025, Retained Earnings is expected to decline to about 30.2 M. In addition to that, Retained Earnings Total Equity is expected to decline to about 30.9 M
| Last Reported | Projected for Next Year | ||
| Dividends Paid | 13.7 M | 8.5 M |
There are various types of dividends Iradimed can pay to its shareholders, and the actual value of the dividend is determined on a per-share basis. It is to be paid equally to all of Iradimed shareholders on a specific date, known as the payable date. The cash dividend is the most common type of dividend payment - it is the payment of actual cash from Iradimed Co directly to its shareholders. There are other types of dividends that companies can issue, such as stock dividends or asset dividends. When Iradimed pays a dividend, it has no impact on its enterprise value. It does, however, lowers the Equity Value of Iradimed by the value of the dividends paid out.
Iradimed Growth Indicators
Investing in growth stocks can be very risky. If the company such as Iradimed does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 12.8 M | |
| Quarterly Earnings Growth Y O Y | 0.152 | |
| Forward Price Earnings | 35.0877 |
Complementary Tools for Iradimed Stock analysis
When running Iradimed's price analysis, check to measure Iradimed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Iradimed is operating at the current time. Most of Iradimed's value examination focuses on studying past and present price action to predict the probability of Iradimed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Iradimed's price. Additionally, you may evaluate how the addition of Iradimed to your portfolios can decrease your overall portfolio volatility.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |